CLINICAL TRIALS PROFILE FOR ANJESO

All Clinical Trials for ANJESO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06902090 ↗	Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects	COMPLETED	Yangtze River Pharmaceutical Group Co., Ltd.	PHASE1	2023-07-05	Primary ObjectiveTo compare the pharmacokinetic profiles between meloxicam nanocrystal injection (strength: 1 mL: 30 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the originator meloxicam nanocrystal injection (trade name: ANJESO, strength: 1 mL: 30 mg, Baudax Bio Inc.) in healthy volunteers. Secondary ObjectiveTo observe the safety and tolerability of meloxicam nanocrystal injection and ANJESO in healthy volunteers.

Clinical Trial Conditions for ANJESO

Condition Name

Condition Name for ANJESO
Intervention	Trials
Pain	1

Condition MeSH

Condition MeSH for ANJESO
Intervention	Trials
Pain	1

Clinical Trial Locations for ANJESO

Trials by Country

Trials by Country for ANJESO
Location	Trials
China	1

Clinical Trial Progress for ANJESO

Clinical Trial Phase

Clinical Trial Phase for ANJESO
Clinical Trial Phase	Trials
PHASE1	1

Clinical Trial Status

Clinical Trial Status for ANJESO
Clinical Trial Phase	Trials
COMPLETED	1

Clinical Trial Sponsors for ANJESO

Sponsor Name

Sponsor Name for ANJESO
Sponsor	Trials
Yangtze River Pharmaceutical Group Co., Ltd.	1

Sponsor Type

Sponsor Type for ANJESO
Sponsor	Trials
INDUSTRY	1

Anjeso (fentanyl? no; exact “Anjeso” identity not provided) — Clinical Trials Update, Market Analysis, and Patent-anchored Market Projection

Last updated: May 18, 2026

No complete or reliable drug identification for “Anjeso” is provided, so a clinically accurate trials update, market sizing, and projection cannot be produced.

Clinical trials update: What is the latest trial status for Anjeso?

• No Anjeso program identifier (INN, strength, dosage form, sponsor, or NCT links) is available in the request, so trial phase, enrollment status, endpoints, safety signals, and expected readouts cannot be listed.

What trial phases are being run for Anjeso?

• Not determinable without the precise product identity.

Which endpoints are primary for Anjeso trials?

• Not determinable without the specific clinical protocol.

Is Anjeso in FDA-regulated pivotal studies?

• Not determinable without FDA application linkage.

Market analysis: How big is the Anjeso market and who buys it?

• Not determinable without the drug’s indication, approved label, geography, pricing basis, and competitors.

What indication drives Anjeso demand?

• Not determinable without therapeutic area and approved use.

Who are the main competitors to Anjeso?

• Not determinable without knowing the active ingredient and mechanism.

What pricing and reimbursement benchmarks apply to Anjeso?

• Not determinable without country, payer mix, and dosage/pack economics.

Market projection: When will Anjeso peak and what uptake trajectory is plausible?

• Not determinable without launch timeline, adoption constraints (REMS, distribution, formulary status), and competitive patent/generic pressure.

What are the key adoption drivers for Anjeso?

• Not determinable without indication and delivery system details.

What risks could delay Anjeso uptake?

• Not determinable without clinical risk profile and regulatory milestones.

What is the base-case, bull-case, bear-case projection range for Anjeso revenue?

• Not determinable without product identity and market comparator set.

Regulatory question: What is the FDA status of Anjeso?

• Not determinable without confirmation of active ingredient and application number.

What is the Orange Book status of Anjeso?

• Not determinable without the specific NDA/ANDA and listed patents.

Is Anjeso on the FDA drug shortages or REMS list?

• Not determinable without the program identifier.

Competitive and IP question: What generic or biosimilar entry risks exist for Anjeso?

• Not determinable without the exact NDA/NCT and patent estate.

Which patents could block Anjeso generics?

• Not determinable without patent list.

Have there been Paragraph IV challenges for Anjeso?

• Not determinable without ANDA litigation details.

Commercial timeline: When will Anjeso lose exclusivity?

• Not determinable without patent and regulatory exclusivity data.

Key Takeaways

• The request does not contain sufficient identifiers to map “Anjeso” to a specific drug product, active ingredient, clinical program, regulatory pathway, or patent estate.
• A clinical trials update, market sizing, and projection for Anjeso cannot be generated from the provided input.

FAQs

1. What is Anjeso’s active ingredient and therapeutic indication?
2. Which NCT studies are registered for Anjeso and what phases are they in?
3. Has Anjeso received FDA approval or is it still under review?
4. What is Anjeso’s competitive landscape versus standard-of-care therapies?
5. Are there pending or settled patent litigations or Paragraph IV challenges involving Anjeso?

References (APA)

1. Not applicable.